Recently, Centivis participated in the virtual World Biomarkers and CDx Summit 2021, which saw industry, Payer, medical providers and patient associations come together to discuss challenges in companion diagnostics.
Centivis Founder Norbert Farkas participated in a panel discussion entitled “Demonstrating Clinical Utility to Engage with Payors & Secure Reimbursement”, where experts shared US and European perspectives on the topic.
3 key takeaways:
1. Access to innovative diagnostics such as next-generation sequencing is naturally higher in academic centers than hospitals nearer to the community. Reimbursement of new technologies and education of the wider medical community have to go hand-in-hand to promote widespread access and reduce inequalities.
2. Demonstrating clinical utility is not only a matter of generating evidence but collaborating with the healthcare ecosystem along the way. A case in point is Oncotype Dx, a breast cancer diagnostic, was able to establish a tariff in Germany with its robust TAILORx trial with more than 10,000 women enrolled.
This trial was a multi-stakeholder initiative involving the US National Cancer Institute and the ECOG-ACRIN Cancer Research Group (a network of researchers and hospitals participating in cancer research), which boosted its credibility.
3. Diagnostics are more than simple blood tests and traditional biomarkers. The field is rapidly evolving with digital biomarkers and AI solutions. Health systems need to keep up with these changes and create clear pathways to reward such innovation.
Want to know more about diagnostics in Europe? Contact us at info@centivis.com